Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exploratory study on the influence of nemolizumab on DLST in healthy volunteers and atopic dermatitis patients
jRCT1050240222Completed
- Sponsor
- Maruho Co., Ltd.
- Start
- Dec 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label trial of nemolizumab in atopic dermatitis (AD) (2 arms), sponsored by Maruho Co., Ltd. Primary endpoint: DLST positive rate. Started Dec 2024; status: completed.
02
Drugs
nemolizumab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on jRCT1050240222.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1050240222.